黄连治疗炎症性肠病的药理、药动学与临床证据追踪
该综述以黄连和黄连素治疗炎症性肠病(IBD)为主题,检索Google Scholar、PubMed、Web of Science、CNKI等数据库文献。黄连常与其他草药配伍用于中药复方治疗IBD,但单味黄连或提取物治疗IBD的研究较少;黄连素是代表性有效成分,主要通过抑制氧化应激、镇痛、保护肠黏膜上皮屏障、调节T辅助细胞及抗菌活性发挥治疗作用。多数临床研究需更严格规范开展以确保安全性和有效性。
要点
- 黄连常以复方形式用于IBD治疗,单味黄连或提取物的疗效研究较少。
- 黄连素是黄连治疗IBD的代表性有效成分,具有多靶点治疗作用。
- 现有临床研究多需更严格规范开展,以确证疗效与安全性。
核心结论
- 黄连素被认为是黄连中代表性有效成分,但黄连中多种其他化学成分也对IBD有治疗作用,需深入研究。
- 需开展临床试验明确黄连化学成分治疗IBD的有效性、安全性及体内外分子机制。
研究设计与样本
- 综述检索Google Scholar、PubMed、Web of Science、CNKI等数据库,以黄连和IBD为主要关键词。
主要发现
- 黄连常与其他草药配伍用于大量中药复方治疗IBD,但单味黄连或提取物治疗该病的研究较少。
- 黄连素治疗IBD的研究近年快速增长,但系统全面的综述较少。
- 黄连活性成分主要通过抑制氧化应激、镇痛、保护肠黏膜上皮屏障、调节T辅助细胞及抗菌活性治疗IBD。
- 近年多数临床研究需更严格规范开展以确保安全性和有效性。
临床怎么用
- 临床可关注黄连素作为黄连治疗IBD的代表性有效成分,但单味黄连或提取物的疗效证据有限。
- 使用黄连及其成分治疗IBD时,应参考复方配伍传统并关注现有临床研究的规范性不足。
局限性
- 单味黄连或提取物治疗IBD的研究较少。
- 多数临床研究需更严格规范开展以确保安全性和有效性。
- 系统全面的黄连及黄连素治疗IBD综述较少。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
ETHNOPHARMACOLOGICAL RELEVANCE: Coptis chinensis (C. chinensis, Huanglian in Chinese), a famous traditional herbal medicine used for clearing heat and detoxification since thousands of years ago, is widely and traditionally used for clinical treatment of stomach inflammation, duodenum and digestive tract ulcers alone or through combing with other herbs in compound formulations. AIM OF THE REVIEW: Through literature reviews of C. chinensis and berberine (one of the most important bioactive compounds derived from this plant) for the treatment of inflammatory bowel disease (IBD), this review aims to provide beneficial information for further exploration of the potent bioactive constituents from C. chinensis, deep investigation on the molecular mechanisms for the treatment of IBD, as well as further research and development of brand new products from C. chinensis for clinical therapy of IBD. METHODS: "C. chinensis" and "IBD" were selected as the main keywords, and various online search engines, such as Google Scholar, PubMed, Web of Science, China National Knowledge Infrastructure database (CNKI) and other publication resources, were used for searching literatures. RESULTS: To present, C. chinensis together with other herbs are involved in plenty of Chinese herbal prescriptions for the treatment of IBD, but little research focused on the single therapeutic effects of C. chinensis or extracts from this herb for the treatment of this disease. Berberine, one of important and representative bioactive compound isolated from C. chinensis, was reported to treat IBD effectively at a big arising speed in recent years. However, systematically and comprehensively reviews on the research of C. chinensis and berberine for the treatment of IBD from the aspects of chemical constituents, pharmacological effects, pharmacokinetics as well as clinical studies are seldom accomplished by researchers. Bioactive components from C. chinensis exert therapeutic effects for the treatment of IBD mainly through the inhibition of oxidative stress, antinociception, protection of intestinal mucosal epithelial barrier, regulation of T helper cells, as well as antibacterial activity. Although numerous studies on bioactive compounds from C. chinense have been performed by clinical investigators in recent years, most of them should be performed in a more strict and standard way to ensure the safety and efficacy of these compounds. CONCLUSIONS: Berberine is considered as the representative and effective component from C. chinensis, but many other chemical components isolated from C. chinensis also have therapeutic effects for the treatment of IBD, which need deep research and further exploration. To accelerate research and development of C. chinensis and its bioactive components for the treatment of IBD, clinical trials are needed to clarify the effectiveness and safety of these chemical components from C. chinensis, as well as their molecular mechanisms for IBD treatment in vitro and in vivo. It is believed that continuous research and exploration on C. chinensis together with its bioactive compounds will bring great hope to the treatment of IBD.
引用
- Yang Y, Vong CT, Zeng S, et al. Tracking evidences of Coptis chinensis for the treatment of inflammatory bowel disease from pharmacological, pharmacokinetic to clinical studies. J Ethnopharmacol. 2020. PMID: 33181286. doi:10.1016/j.jep.2020.113573
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。